← Leaderboards
Anthony G Letai
Dana-Farber Cancer Inst
$22,380,537
Attributed
$22,380,537
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,380,537 · 14
By mechanism
P01$9,050,741 · 8
R35$7,030,366 · 1
R01$5,158,045 · 2
K08$644,060 · 1
R21$413,903 · 1
P30$83,422 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Jacqueline Suen Garcia$1,292,805
- Geoffrey I Shapiro$18,639,470
- Alan David D'andrea$28,094,196
- Edward Paul Harvey$154,380
- Irene M. Ghobrial$24,445,801
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisApoptoticCellsBaseSignal TransductionMitochondriaPharmaceutical PreparationsResponseCancer CellTumorCessation Of LifeProteinsIn VivoNovel StrategiesMalignant NeoplasmsChemotherapySmall MoleculeSamplingCell DeathMolecularChronic Lymphocytic LeukemiaClinical TrialsPathway InteractionsLaboratories
Grant awards (58)
Reading mitochondrial apoptotic signaling to identify active cancer therapeutics$1,060,200
R35 · FY2025 · CA · contact PI
Targeting BFL-1 in Acute Myelogenous Leukemia$389,348
P01 · FY2025 · CA · contact PI
Functional identification of drug response and resistance in Richter's Syndrome$291,373
P01 · FY2025 · CA · contact PI
Reading mitochondrial apoptotic signaling to identify active cancer therapeutics$1,007,191
R35 · FY2024 · CA · contact PI
Directing AML therapy with BH3 profiling$374,065
P01 · FY2024 · CA · contact PI
Functional identification of drug response and resistance in Richter's Syndrome$281,228
P01 · FY2024 · CA · contact PI
Reading mitochondrial apoptotic signaling to identify active cancer therapeutics$1,016,184
R35 · FY2023 · CA · contact PI
Directing AML therapy with BH3 profiling$385,971
P01 · FY2023 · CA · contact PI
Functional identification of drug response and resistance in Richter's Syndrome$285,531
P01 · FY2023 · CA · contact PI
Program 06 Lymphoma and Myeloma$41,711
P30 · FY2023 · CA · contact PI
Reading mitochondrial apoptotic signaling to identify active cancer therapeutics$1,038,996
R35 · FY2022 · CA · contact PI
Directing AML therapy with BH3 profiling$380,350
P01 · FY2022 · CA · contact PI
Functional identification of drug response and resistance in Richter's Syndrome$285,467
P01 · FY2022 · CA · contact PI
Program 06 Lymphoma and Myeloma$41,711
P30 · FY2022 · CA · contact PI
Reading mitochondrial apoptotic signaling to identify active cancer therapeutics$1,037,388
R35 · FY2021 · CA · contact PI
Directing AML therapy with BH3 profiling$388,111
P01 · FY2021 · CA · contact PI
Functional identification of drug response and resistance in Richter's Syndrome$298,837
P01 · FY2021 · CA · contact PI
Reading mitochondrial apoptotic signaling to identify active cancer therapeutics$1,060,200
R35 · FY2020 · CA · contact PI
Directing AML therapy with BH3 profiling$394,614
P01 · FY2020 · CA · contact PI
Functional identification of CLL drug response and resistance$305,395
P01 · FY2020 · CA · contact PI
Reading mitochondrial apoptotic signaling to identify active cancer therapeutics$810,207
R35 · FY2019 · CA · contact PI
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity$374,990
R01 · FY2019 · CA · contact PI
Functional identification of CLL drug response and resistance$298,494
P01 · FY2019 · CA · contact PI
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity$226,819
R01 · FY2019 · CA · contact PI
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity$386,588
R01 · FY2018 · CA · contact PI
Mitochondrial determination of response to targeted AML therapies$368,813
P01 · FY2018 · CA · contact PI
Functional identification of CLL drug response and resistance$315,164
P01 · FY2018 · CA · contact PI
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity$230,366
R01 · FY2018 · CA · contact PI
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity$386,588
R01 · FY2017 · CA · contact PI
Mitochondrial determination of response to targeted AML therapies$368,794
P01 · FY2017 · CA · contact PI
Functional identification of CLL drug response and resistance$315,164
P01 · FY2017 · CA · contact PI
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity$390,540
R01 · FY2016 · CA · contact PI
Functional identification of CLL drug response and resistance$373,898
P01 · FY2016 · CA · contact PI
Mitochondrial determination of response to targeted AML therapies$368,774
P01 · FY2016 · CA · contact PI
Probing mitochondria and personalizing leukemia therapy with BH3 profiling$315,153
R01 · FY2016 · CA · contact PI
Mitochondrial determination of response to targeted AML therapies$368,732
P01 · FY2015 · CA · contact PI
Probing mitochondria and personalizing leukemia therapy with BH3 profiling$315,153
R01 · FY2015 · CA · contact PI
Investigation of therapeutic modulators of apoptotic priming in pancreatic cancer$188,138
R21 · FY2015 · CA · contact PI
Mitochondrial determination of response to targeted AML therapies$381,844
P01 · FY2014 · CA · contact PI
Mitochondrial Determinants of Chemotherapy Responses in Cancer Cells$328,542
P01 · FY2014 · CA · contact PI
Probing mitochondria and personalizing leukemia therapy with BH3 profiling$305,698
R01 · FY2014 · CA · contact PI
Investigation of therapeutic modulators of apoptotic priming in pancreatic cancer$225,765
R21 · FY2014 · CA · contact PI
Mitochondrial Determinants of Chemotherapy Responses in Cancer Cells$398,278
P01 · FY2013 · CA · contact PI
Probing mitochondria and personalizing leukemia therapy with BH3 profiling$296,244
R01 · FY2013 · CA · contact PI
Mitochondrial Determinants of Chemotherapy Responses in Cancer Cells$422,791
P01 · FY2012 · CA · contact PI
Probing mitochondria and personalizing leukemia therapy with BH3 profiling$315,153
R01 · FY2012 · CA · contact PI
Mitochondrial Determinants of Chemotherapy Responses in Cancer Cells$336,371
P01 · FY2011 · CA · contact PI
A Novel Strategy for Defining and Targeting Cancer Addiction to Anti-Apoptotic BC$315,153
R01 · FY2011 · CA · contact PI
Mitochondrial Determinants of Chemotherapy Responses in Cancer Cells$344,792
P01 · FY2010 · CA · contact PI
A Novel Strategy for Defining and Targeting Cancer Addiction to Anti-Apoptotic BC$324,900
R01 · FY2010 · CA · contact PI
A Novel Strategy for Defining and Targeting Cancer Addiction to Anti-Apoptotic BC$324,900
R01 · FY2009 · CA · contact PI
A Novel Strategy for Defining and Targeting Cancer Addiction to Anti-Apoptotic BC$324,900
R01 · FY2008 · CA · contact PI
A Novel Strategy for Defining and Targeting Cancer Addiction to Anti-Apoptotic BC$324,900
R01 · FY2007 · CA · contact PI
Controlling the BCL-2 Pathway of Mitochondrial Apoptosis$101,358
K08 · FY2007 · CA · contact PI
Controlling the BCL-2 Pathway of Mitochondrial Apoptosis$135,837
K08 · FY2006 · CA · contact PI
Controlling the BCL-2 Pathway of Mitochondrial Apoptosis$135,837
K08 · FY2005 · CA
Controlling the BCL-2 Pathway of Mitochondrial Apoptosis$135,658
K08 · FY2004 · CA
Controlling the BCL-2 Pathway of Mitochondrial Apoptosis$135,370
K08 · FY2003 · CA